Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 3/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.33 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 3/20 | 0.32 |
| ▸ | CYBB | P04839 | 1/20 | 0.30 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14746268 | 0.82 | JAK2 (0.36) | SGK1PDPK1JAK2ILK | |
| SCHEMBL26675449 | 0.76 | JAK2 (0.44) | PDPK1JAK2GAAKDM4E | |
| SCHEMBL12467662 | 0.75 | PDPK1 (0.36) | PDPK1JAK2GAAKDM4ECYP3A4 | |
| SCHEMBL26675436 | 0.75 | PDPK1 (0.38) | PDPK1KDM4E | |
| SCHEMBL26675423 | 0.72 | GRM4 (0.34) | — | |
| SCHEMBL29768225 | 0.72 | GRM4 (0.34) | — | |
| SCHEMBL23356033 | 0.69 | JAK2 (0.50) | JAK2GAAKDM4E | |
| SCHEMBL23356139 | 0.69 | EGFR (0.44) | KDM4ECYP3A4 | |
| SCHEMBL175432 | 0.69 | RET (0.38) | SGK1PDPK1JAK2GAAKDM4E | |
| SCHEMBL30440210 | 0.69 | RET (0.38) | SGK1PDPK1JAK2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024224298-A1 | METHOD OF PREPARING 4-AMINOINDAN AND METHOD OF PREPARING DIHYDROINDENYL-PYRAZOLO[3,4-B]PYRIDINE-AMINE COMPOUND | 제이더블유중외제약 주식회사 | 2024-10-31 | — | — | WO | disclosed |